Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective aldosterone blockade reduces mortality after MI.

Mark B Stephens1

  • 1Flight Line Clinic Naval Hospital, Sigonella, Italy. mbstephens@sig.med.navy.mil

The Journal of Family Practice
|August 6, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visual thinking Strategies and the peril of 'see one, do one, teach one'.

International review of psychiatry (Abingdon, England)·2024
Same author

Removing the COVID-19 Vaccination Requirement for the Military Increases the United States' National Security Concerns.

Family medicine·2023
Same author

The Opaque Language of Sexuality: Medical Students' and Providers' Beliefs About Virginity.

Archives of sexual behavior·2023
Same author

Visual Thinking Strategies in Medical Education: Staying Open to Possibilities.

Academic medicine : journal of the Association of American Medical Colleges·2023
Same author

Promotion Preparation Tips for Academic Family Medicine Educators.

Family medicine·2022
Same author

Taking Off the Mask: Impostorism and Medical Education.

PRiMER (Leawood, Kan.)·2022
Same journal

Does taking BP medicine at night (vs morning) result in fewer cardiovascular events?

The Journal of family practice·2023
Same journal

Preventing RSV in children and adults: A vaccine update.

The Journal of family practice·2023
Same journal

Essential oils: How safe? How effective?

The Journal of family practice·2023
Same journal

51-year-old woman • History of Graves disease • General fatigue, palpitations, and hand tremors • Dx?

The Journal of family practice·2023
Same journal

Renewing the dream.

The Journal of family practice·2023
Same journal

55-year-old woman • Myalgias and progressive symmetrical proximal weakness • History of unilateral renal agenesis, type 2 diabetes, and hyperlipidemia • Dx?

The Journal of family practice·2023
See all related articles

Eplerenone reduces mortality in heart failure patients after myocardial infarction. Spironolactone offers similar benefits at a lower cost, providing a cost-effective treatment option.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Eplerenone, a selective mineralocorticoid receptor antagonist, is FDA-approved for hypertension.
  • Eplerenone has demonstrated efficacy in reducing mortality post-myocardial infarction in patients with left ventricular dysfunction and heart failure.

Discussion:

  • This research builds upon previous findings that spironolactone also reduces mortality in similar patient populations.
  • A key consideration is the comparative cost-effectiveness of eplerenone versus spironolactone.

Key Insights:

  • Selective mineralocorticoid receptor antagonism is a validated therapeutic strategy for post-myocardial infarction care.
  • Eplerenone's established role in hypertension management extends to post-MI heart failure treatment.
  • Spironolactone presents a lower-cost alternative with comparable mortality benefits.

Related Experiment Videos

Outlook:

  • Further research may explore head-to-head comparisons of eplerenone and spironolactone in specific heart failure phenotypes.
  • Investigating the long-term adherence and outcomes associated with both agents is warranted.
  • Optimizing treatment guidelines to incorporate cost-effectiveness alongside clinical efficacy is crucial.